Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study-Reference-Cited by-同舟云学术

Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study

Published:2022-08 Issue: Volume:928 Page:175053
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Jia Ruoyu,Zhang Xuejie,Xu Yizhou,Zheng Zhifang,Jiang Luhua,Zhang Xin,Sun Chen,Wu Xin,Li Shulin,Raj Ashok,Sun Dong^ORCID

Publisher

Elsevier BV

Subject

Pharmacology

Reference65 articles.

1. Transient and sustained increases in glomerular permeability following ANP infusion in rats;Axelsson;Am. J. Physiol. Ren. Physiol.,2011

2. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy;Benigni;Kidney Int.,2004

3. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy);Brenyo;J. Am. Coll. Cardiol.,2011

4. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo;Canaan-Kuhl;Kidney Int.,1998

5. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats;Cheng;J. Hypertens.,2005

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction;Pharmacological Research;2024-06

2. Ist Sacubitril/Valsartan bei fortgeschrittener Nierenerkrankung und Dialysepflichtigkeit eine gute Option?;Die Nephrologie;2024-04-09

3. Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease;Journal of Cardiovascular Pharmacology and Therapeutics;2024-01

4. Omaveloxolone ameliorates isoproterenol-induced pathological cardiac hypertrophy in mice;Free Radical Research;2023-12-25

5. Device therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction;Heart Failure Reviews;2023-11-08